Trump Administration Launches Tariff Probe into Medtech and Pharmaceutical Industries

Trump administration; tariffs; medtech industry; pharmaceutical imports; Section 232 investigation; semiconductor tariffs; national security; supply chain; manufacturing; medical devices

Trump Administration May Exempt Some Pharma Products from Future Tariffs in Trade Policy Shift

pharmaceutical tariffs; tariff exemptions; Trump administration; Section 232 investigation; trade policy; reciprocal tariffs; generic pharmaceuticals; active pharmaceutical ingredients; commerce secretary authority

Pfizer CEO Bourla suggests pharma tariffs will focus on US adversaries, not allies

Pharmaceutical tariffs, Section 232 investigation, Albert Bourla, national security, trade policy, manufacturing investments, Trump administration, supply chain concerns

U.S. Biotechs Reveal Tariff Exposure as Trade Inquiry Signals Imminent Pharmaceutical Tariffs

U.S. biotech, pharmaceutical tariffs, Section 232 investigation, supply chain exposure, trade policy, import costs, reshoring manufacturing, drug pricing, global supply chain, pharmaceutical ingredients, regulatory impact